Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Plus Therapeutics entered an Equity Distribution Agreement that permits it to sell up to $17,350,000 of common stock through an at-the-market offering with Canaccord Genuity as sales agent.
Shares will be sold from time to time under a Form S-3 shelf registration, with Canaccord earning a 3.0% commission on gross proceeds plus up to $75,000 of reimbursed expenses. Plus Therapeutics can choose when and if to sell, set minimum acceptable prices, and suspend or terminate the program. Net proceeds are intended for general corporate purposes and working capital.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ATM program size: $17,350,000
Sales agent commission: 3.0% of gross proceeds
Expense reimbursement: $75,000
3 metrics
ATM program size
$17,350,000
Maximum aggregate offering price of common stock under Equity Distribution Agreement
Sales agent commission
3.0% of gross proceeds
Commission payable to Canaccord Genuity on stock sold
Expense reimbursement
$75,000
Reimbursement cap for Canaccord’s documented out-of-pocket expenses
Key Terms
Equity Distribution Agreement, at the market offering, Registration Statement on Form S-3, General Instruction I.B.6 of Form S-3
4 terms
Equity Distribution Agreement financial
"entered into an Equity Distribution Agreement (the “Distribution Agreement”)"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at the market offering financial
"method permitted by law deemed to be an “at the market offering”"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"pursuant to the Company’s Registration Statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
General Instruction I.B.6 of Form S-3 regulatory
"subject to the limitations of General Instruction I.B.6 of Form S-3"
FAQ
What equity offering did Plus Therapeutics (PSTV) announce in this 8-K?
Plus Therapeutics put in place an at-the-market equity program allowing sales of up to $17,350,000 of common stock. Shares may be issued periodically through Canaccord Genuity on Nasdaq under an effective Form S-3 shelf registration statement.
How will Plus Therapeutics (PSTV) use proceeds from the $17,350,000 ATM program?
Plus Therapeutics intends to use net proceeds from any stock sales for general corporate purposes and working capital. This typically includes funding operations, pipeline development, and corporate needs, though specific allocations are not detailed in the disclosed agreement summary.
What fees will Plus Therapeutics (PSTV) pay Canaccord under the Equity Distribution Agreement?
Plus Therapeutics will pay Canaccord Genuity a 3.0% commission on gross proceeds from any share sales and reimburse $75,000 of reasonable documented expenses. These costs are tied directly to the execution and maintenance of the at-the-market common stock offering program.
What regulatory framework governs Plus Therapeutics’ (PSTV) new ATM offering?
The at-the-market offering is conducted under Plus Therapeutics’ Registration Statement on Form S-3 and a related prospectus supplement. It is classified as an “at the market offering” under Rule 415(a)(4) and remains subject to Form S-3 General Instruction I.B.6 limits.